eFFECTOR Appoints Kristen Harrington-Smith to Board of Directors
16. Februar 2022 08:30 ET
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the...
eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference
09. Februar 2022 16:00 ET
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation...
eFFECTOR Therapeutics Provides Pipeline and Business Updates
24. Januar 2022 16:00 ET
|
eFFECTOR Therapeutics, Inc.
Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) evaluating frontline maintenance in PD-L1 ≥1% patient...
eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology
24. November 2021 08:00 ET
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of...
eFFECTOR Therapeutics to Participate in The JMP Securities Hematology and Oncology Summit
22. November 2021 08:00 ET
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors...
eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
08. November 2021 07:00 ET
|
eFFECTOR Therapeutics, Inc.
• Continuing to enroll patients in Phase 2b KICKSTART study of tomivosertib in combination with pembrolizumab, a U.S. Food and Drug Administration (FDA) approved PD-1 inhibitor • Selected...
eFFECTOR Appoints Barbara Klencke, M.D., to Board of Directors
01. November 2021 16:05 ET
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer,...
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
26. Oktober 2021 08:00 ET
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer,...
Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
07. Oktober 2021 16:30 ET
|
eFFECTOR Therapeutics, Inc.
• Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem-cell signaling pathways • Induced beneficial changes in the tumor microenvironment by increasing...
Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
30. September 2021 16:32 ET
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer,...